-

09:34:35 PM

ADMP Stock News

ADMP - Adamis Pharmaceuticals Corp

06/01/22 8:00 AM

Nasdaq : ADMP

clinical trialcovid-19

Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose,

RHEA-AI

neutral

05/26/22 4:05 PM

Nasdaq : ADMP

management

Adamis Appoints Vickie Reed to Board of Directors

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of

RHEA-AI

neutral

05/18/22 5:00 PM

Nasdaq : ADMP

management

Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and

RHEA-AI

very positive

05/16/22 4:35 PM

Nasdaq : ADMP

earnings

Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and

RHEA-AI

negative

05/09/22 5:56 PM

Nasdaq : ADMP

earnings

Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference

RHEA-AI

neutral

03/31/22 4:49 PM

Nasdaq : ADMP

earnings

Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and

RHEA-AI

neutral

03/31/22 4:14 PM

Nasdaq : ADMP

US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product

USWM, LLC (US WorldMeds), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S. launch and availability of ZIMHI™

RHEA-AI

neutral

03/24/22 7:30 AM

Nasdaq : ADMP

earnings

Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor

RHEA-AI

neutral

03/22/22 7:30 AM

Nasdaq : ADMP

Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston,

RHEA-AI

very negative

03/21/22 4:05 PM

Nasdaq : ADMP

Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level. The batches in the

RHEA-AI

very negative

1 2 3 4 5 6 7 Next

ADMP Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.adamispharmaceuticals.com
CeoDennis Carlo
Security nameAdamis Pharmaceuticals Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees130
Tags
- Health Technology
- Pharmaceuticals: Other
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address11682 El Camino Real Ste 300
StateCalifornia
CitySan Diego
Zip92130
CountryUS
Phone18589972400

About Adamis Pharmaceuticals Corp

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. Forward Looking Statements